Drug Prices
Commentary
Trump’s Plan To Peg Drug Prices to Foreign Countries Could Backfire
President Trump famously quipped during his run for a second term that he had “concepts of a plan” to fix health care. That plan finally came together in January — and congressional Republicans are eager to codify its concepts into law. Most of Mr. Trump’s “Great Healthcare Plan” is promising. ...
Commentary
Most-Favored-Nation Pricing Would Import Europe’s Drug Rationing
President Trump’s State of the Union address featured several promising healthcare ideas. Expanding access to patient-owned health savings accounts and routing federal subsidies through them, rather than through insurance companies, would unleash competition by empowering consumers to spend their healthcare dollars as they see fit. So would stronger price transparency ...
Commentary
In the rush to hold insurers to account, don’t forget about hospitals
When asked to account for the skyrocketing cost of health coverage before two House committees last Thursday, the chief executives of five of America’s largest health insurance companies pointed fingers. Don’t look at us, they said. Look at hospitals and drugmakers. Read the op-ed here.
Commentary
Open, Competitive Market Will Make Trump’s Health Plan Great
President Trump’s recently released Great Healthcare Plan offers several welcome reforms. It endeavors to put patients first by fostering greater price transparency and taking steps to lower health insurance premiums. Its approach to prescription drug policy is a bit more mixed. Read the op-ed here.
Commentary
CMS Officials Are Undermining Trump’s Push For Affordable Drugs
Officials at the Centers for Medicare and Medicaid Services just undermined President Trump’s efforts to make prescription drugs more affordable. Earlier this week, CMS announced the next 15 medicines that will face price caps under Medicare’s Drug Price “Negotiation” Program, a core component of the Inflation Reduction Act signed into ...
Drug Prices
ISSUE BRIEF: Biopharma Drug Makers Are Not the Most Profitable Players in Health Care
A new issue brief released by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute finds that innovative drug manufacturers earn some of the lowest risk-adjusted returns in the U.S. health care system, despite making the largest investments in research and development. The findings challenge the ...
Drug Prices
PRI Files Amicus Brief in Major Supreme Court Case That Could Upend Future Medical Innovation Nationwide
SACRAMENTO – California-based free market think tank the Pacific Research Institute announced today that it has filed an amicus curiae brief urging the U.S. Supreme Court to hear two cases challenging the federal government’s new prescription drug pricing program enacted under the Inflation Reduction Act. The cases, Janssen Pharmaceuticals, Inc. ...
Blog
How can we make drugs more affordable without sacrificing future cures?
How can we make drugs more affordable without sacrificing future cures? To a large extent, the current system works fairly well already to make most of the drugs that Americans take affordable. And that’s because of our robust generics market. Around 90% of prescriptions filled each year are for generics ...
Blog
Do price controls affect which drugs patients have access to and how soon?
Do price controls affect which drugs patients have access to and how soon? They absolutely do. Just look at the situation in Europe. For years, drug companies have been choosing to withhold certain medicines from European markets rather than accept the price constraints imposed by governments there. As a result, ...
Blog
How do price controls damage innovation?
What role do intellectual property laws play in encouraging innovation? They are absolutely essential. IP protections like patents reward those who succeed in creating new medicines and ushering them through the regulatory approval process. They do this by guaranteeing that the IP rights holder behind a new drug will have ...
Trump’s Plan To Peg Drug Prices to Foreign Countries Could Backfire
President Trump famously quipped during his run for a second term that he had “concepts of a plan” to fix health care. That plan finally came together in January — and congressional Republicans are eager to codify its concepts into law. Most of Mr. Trump’s “Great Healthcare Plan” is promising. ...
Most-Favored-Nation Pricing Would Import Europe’s Drug Rationing
President Trump’s State of the Union address featured several promising healthcare ideas. Expanding access to patient-owned health savings accounts and routing federal subsidies through them, rather than through insurance companies, would unleash competition by empowering consumers to spend their healthcare dollars as they see fit. So would stronger price transparency ...
In the rush to hold insurers to account, don’t forget about hospitals
When asked to account for the skyrocketing cost of health coverage before two House committees last Thursday, the chief executives of five of America’s largest health insurance companies pointed fingers. Don’t look at us, they said. Look at hospitals and drugmakers. Read the op-ed here.
Open, Competitive Market Will Make Trump’s Health Plan Great
President Trump’s recently released Great Healthcare Plan offers several welcome reforms. It endeavors to put patients first by fostering greater price transparency and taking steps to lower health insurance premiums. Its approach to prescription drug policy is a bit more mixed. Read the op-ed here.
CMS Officials Are Undermining Trump’s Push For Affordable Drugs
Officials at the Centers for Medicare and Medicaid Services just undermined President Trump’s efforts to make prescription drugs more affordable. Earlier this week, CMS announced the next 15 medicines that will face price caps under Medicare’s Drug Price “Negotiation” Program, a core component of the Inflation Reduction Act signed into ...
ISSUE BRIEF: Biopharma Drug Makers Are Not the Most Profitable Players in Health Care
A new issue brief released by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute finds that innovative drug manufacturers earn some of the lowest risk-adjusted returns in the U.S. health care system, despite making the largest investments in research and development. The findings challenge the ...
PRI Files Amicus Brief in Major Supreme Court Case That Could Upend Future Medical Innovation Nationwide
SACRAMENTO – California-based free market think tank the Pacific Research Institute announced today that it has filed an amicus curiae brief urging the U.S. Supreme Court to hear two cases challenging the federal government’s new prescription drug pricing program enacted under the Inflation Reduction Act. The cases, Janssen Pharmaceuticals, Inc. ...
How can we make drugs more affordable without sacrificing future cures?
How can we make drugs more affordable without sacrificing future cures? To a large extent, the current system works fairly well already to make most of the drugs that Americans take affordable. And that’s because of our robust generics market. Around 90% of prescriptions filled each year are for generics ...
Do price controls affect which drugs patients have access to and how soon?
Do price controls affect which drugs patients have access to and how soon? They absolutely do. Just look at the situation in Europe. For years, drug companies have been choosing to withhold certain medicines from European markets rather than accept the price constraints imposed by governments there. As a result, ...
How do price controls damage innovation?
What role do intellectual property laws play in encouraging innovation? They are absolutely essential. IP protections like patents reward those who succeed in creating new medicines and ushering them through the regulatory approval process. They do this by guaranteeing that the IP rights holder behind a new drug will have ...